Therapeutic antibodies are a type of medication that is designed to target specific proteins in the body that are involved in disease processes. They are typically made from human or animal cells that have been genetically engineered to produce antibodies that can recognize and bind to a specific target protein. Once bound to the target protein, therapeutic antibodies can either block its activity or trigger an immune response against it, depending on the specific mechanism of action. Therapeutic antibodies have been developed to treat a wide range of diseases, including cancer, autoimmune disorders, 感染症, and inflammatory conditions. They are often used in combination with other medications, such as chemotherapy or immunosuppressive drugs, to improve treatment outcomes and reduce side effects. The therapeutic antibodies market in China is likely to register a CAGR of over 26.95% 米ドルの漸進的な成長に伴い 42.7 予測期間中に10億ドル 2023-2029.

この業界レポートは中国市場の市場予測を提供します。, 続いてタイプの詳細な分析. The China market data on therapeutic antibodies can be segmented by type: antibody-drug conjugate (ADC), BsAb, monospecific Ab, その他.

The China therapeutic antibodies market is highly competitive. 現在 2022, the major players in the China therapeutic antibodies market were 3SBio Inc., Bristol-Myers Squibb Company, Chengdu Kanghong Pharmaceutical Group Co. 株式会社, Jiangsu Hengrui Medicine Co. 株式会社, メルク & 株式会社, Novartis International AG, ロシュ・ホールディングAG, Sinopharm Corporation Ltd.

データ中心のレポートは市場動向に焦点を当てています, セグメントの現状と見通し. さまざまな市場セグメントにわたる市場を包括的にカバー, レポートは既存のプレイヤーにとって貴重な資産です, 新規参入者と将来の投資家.

このレポートを購入する理由?
▹ Get a detailed picture of the China Therapeutic Antibodies Market
▹ Identify segments/areas to invest in over the forecast period in the China Therapeutic Antibodies Market
▹ 競争環境を理解する, 市場の主要企業
▹ Excel 形式でのシナリオ全体の分析を容易にするための市場予測.
▹ 3ヶ月間の戦略コンサルティングとリサーチサポート.
▹ シングルユーザーライセンスに印刷認証を提供.